Caris Life Sciences (CAI) Preferred Stock Liabilities (2024 - 2025)
Caris Life Sciences (CAI) recorded quarterly Preferred Stock Liabilities of $2.2 billion in Q1 2025, up 1.1% quarter-over-quarter from $2.2 billion in Q4 2024.
Caris Life Sciences (CAI) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
Caris Life Sciences' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $2.2 billion for Q1 2025.
- In Q1 2025, Preferred Stock Liabilities changed N/A year-over-year to $2.2 billion; the TTM figure through Mar 2025 stood at $2.2 billion (changed N/A YoY), while the FY2024 annual figure was $2.2 billion, up 4.53% from the prior year.
- Preferred Stock Liabilities was $2.2 billion for Q1 2025 at Caris Life Sciences, up from $2.2 billion in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $2.2 billion in Q1 2025 to a low of $2.2 billion in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Caris Life Sciences | 5.22 Bn | 4.40 Bn | 171.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 2.25 Bn |
| Dec 31, 2024 | 2.22 Bn |
| Sep 30, 2024 | 2.20 Bn |
| Jun 30, 2024 | 2.17 Bn |